Lung cancer is the most commonly diagnosed cancer in Indian men and the leading cause of cancer death overall, with roughly 81,000 new cases recorded each year by the ICMR National Cancer Registry. Most Indian patients still reach a cancer centre after the disease has already spread, which is why the stage at diagnosis changes treatment and outcome more than almost any other variable. This page explains how thoracic oncologists in Delhi, Gurgaon and Noida actually stage lung cancer using the TNM 8th edition, how non-small cell and small cell lung cancer are handled differently, and what families can expect at each stage in an NCR tertiary centre.
What Lung Cancer Staging Actually Means
Lung cancer staging is the formal process of deciding how far the tumour has travelled from its starting point in the bronchus or lung parenchyma. The stage is built from three pieces of information: the size and local invasion of the primary tumour (T), whether regional lymph nodes around the airway and mediastinum are involved (N), and whether the cancer has seeded the other lung, the pleura, the brain, bones, liver or adrenal glands (M). Unlike blood cancers, lung cancer has a single, universally used anatomic system, the UICC/AJCC TNM 8th edition, and every NCCN-aligned hospital in NCR including leading cancer centres reports stage in the same language. (See the UICC TNM classification and the NCI PDQ on NSCLC staging.)
Why Lung Cancer Is Staged With TNM 8 and Not a Risk Score
Lung tumours grow as discrete masses that can be measured on a CT scan, biopsied through a bronchoscope or a percutaneous needle, and tracked on a PET-CT. That anatomy makes them a natural fit for a size-and-spread staging system, which is why the International Association for the Study of Lung Cancer (IASLC) has refined the TNM system through eight editions of patient data. The 8th edition, in use since 2017 and still the reference for every Indian thoracic unit in 2026, was built from a database of more than 94,000 lung cancer patients and is the most prognostically discriminating edition so far. Risk scores such as ELN or IPI, used in leukemia and lymphoma, do not apply here. (See Detterbeck, Chest 2017 on the TNM 8 rationale.)
NSCLC and SCLC: Two Different Staging Worlds
Lung cancer is split into two biologically separate families that are staged and treated very differently. Non-small cell lung cancer (NSCLC) accounts for about 85 percent of Indian cases and is staged by the standard TNM 8 system with stage groupings from IA1 through IVB. Small cell lung cancer (SCLC), a neuroendocrine tumour that makes up the remaining 13 to 15 percent, spreads early through the bloodstream and is still commonly classified as “limited stage” (disease confined to one hemithorax and fitting within a tolerable radiotherapy port) or “extensive stage” (everything beyond that), in addition to a parallel TNM assignment used for trial enrolment. The split matters because a T4N2 NSCLC and a T4N2 SCLC are treated on completely different pathways from day one. (See NCI PDQ on SCLC.)
Subtypes of NSCLC: Adenocarcinoma, Squamous and Large Cell
Within non-small cell lung cancer, the histological subtype changes the treatment decision as much as the stage does. Adenocarcinoma is now the most frequent form seen at leading cancer centres in the region, especially in never-smokers and women, and it is the subtype most likely to carry a targetable driver mutation such as EGFR, ALK, ROS1, BRAF, MET, RET, KRAS G12C or HER2. Squamous cell carcinoma is more closely tied to cigarette and bidi smoking, arises in the central airways, and is rarely driver-positive, so it is treated with chemo-immunotherapy regimens rather than targeted pills. Large cell carcinoma is a diagnosis of exclusion, and rarer variants such as sarcomatoid, adenosquamous and NUT carcinoma go to the tumour board. Reflex NGS testing is now standard at every NCR tertiary centre. (See ESMO NSCLC guidelines.)
The T Descriptor: Tumour Size and Local Invasion in Lung Cancer
The T category in lung cancer TNM 8 is driven by centimetre thresholds that a radiologist measures on the axial CT. T1a is a tumour up to 1 cm, T1b is 1 to 2 cm, T1c is 2 to 3 cm, T2a is 3 to 4 cm, T2b is 4 to 5 cm, T3 is 5 to 7 cm or a tumour of any size that invades the chest wall, phrenic nerve or parietal pericardium, and T4 is above 7 cm or a tumour that invades the mediastinum, diaphragm, heart, great vessels, carina, recurrent laryngeal nerve, oesophagus or vertebral body, or that includes a separate nodule in a different ipsilateral lobe. Visceral pleural invasion upgrades a T1 to T2. These thresholds matter because a tumour that measures 3.1 cm is treated as T2a and crosses into a slightly higher stage grouping than an otherwise identical 2.9 cm tumour. (See the IASLC staging manual.)
The N Descriptor: Hilar, Mediastinal and Supraclavicular Nodes
Nodal staging is arguably the most important single decision in lung cancer, because it often determines whether a patient goes to theatre or to the radiation bunker. N0 means no regional nodal involvement. N1 covers the ipsilateral peribronchial and hilar nodes. N2 covers the ipsilateral mediastinal and subcarinal nodes, and N3 covers contralateral mediastinal, contralateral hilar and any supraclavicular or scalene nodes. The jump from N1 to N2 is the single largest change in treatment intent in non-small cell lung cancer, because pathological N2 disease typically removes upfront surgery as a first step and brings concurrent chemoradiation, neoadjuvant chemo-immunotherapy, or induction therapy into the discussion. EBUS-TBNA at a tertiary cancer centre and a tertiary cancer centre is now the primary tool for confirming N2 disease before committing to a surgical plan.
The M Descriptor: M1a, M1b and M1c Metastatic Disease
M1 disease in lung cancer is not a single bucket. TNM 8 splits it into three subgroups that carry meaningfully different prognoses and treatment options. M1a covers a malignant pleural or pericardial effusion, a contralateral lung nodule, or pleural nodules. M1b is a single extrathoracic metastasis in a single organ, and M1c is multiple extrathoracic metastases or multiple lesions in a single organ. The M1b subgroup is important because oligometastatic lung cancer, defined as up to five metastases on staging imaging, is now treated with curative intent at several NCR centres using stereotactic ablative radiotherapy or metastasectomy on top of systemic therapy, based on evidence from the Gomez et al. phase 2 trial and SABR-COMET.
Stage I NSCLC: What It Looks Like and How It Is Confirmed
Stage I non-small cell lung cancer is a tumour confined to the lung, up to 4 cm in size, with no nodal involvement (T1a–T2a N0 M0). Most stage I cases in NCR are picked up incidentally on a CT ordered for an unrelated reason or on a low-dose CT screen in a heavy smoker. Confirmation always requires a tissue diagnosis, most often through a CT-guided percutaneous core needle biopsy for a peripheral lesion or navigational bronchoscopy for a central one. Staging is completed with a whole-body FDG PET-CT and a contrast brain MRI to rule out occult metastases, because missing a single brain lesion turns a supposed stage I into a stage IV and changes the entire plan. Five-year survival after lobectomy or SBRT for stage IA NSCLC at experienced NCR centres is in the 70 to 90 percent range.
Stage II NSCLC: Larger Tumours and N1 Nodes
Stage II non-small cell lung cancer includes tumours up to 5 cm with N1 nodal involvement (IIA and IIB) and larger tumours up to 7 cm with no nodes. These are still surgically resectable in a fit patient and are still treated with curative intent. The standard plan is an anatomic lobectomy with systematic mediastinal lymph node dissection, done open, VATS or robotic depending on centre experience. A full ipsilateral mediastinal node clearance is essential because up to one in five clinical N1 patients turn out to have occult N2 disease on final pathology, which changes the adjuvant plan. Adjuvant platinum doublet chemotherapy is standard after resection, and for EGFR-mutant patients three years of adjuvant osimertinib is added based on the ADAURA trial.
Stage III NSCLC: The Locally Advanced Middle Ground
Stage III non-small cell lung cancer is the most heterogeneous stage and the hardest one to treat well. IIIA includes T3N1, T4N0-1 and some T1-2N2 tumours. IIIB includes T3-4N2 and T1-2N3. IIIC is T3-4N3. A single-station N2 tumour in a fit patient is often taken to surgery after induction chemo-immunotherapy, while multi-station or bulky N2 and all N3 disease is treated with definitive concurrent chemoradiation. The choice between these two pathways is made in a multidisciplinary thoracic tumour board, and every NCR tertiary centre now runs one. Getting stage III right matters more than almost any other decision in lung oncology because the five-year survival range inside stage III stretches from roughly 15 percent to 55 percent depending on substage and treatment intent.
Stage IV NSCLC: Metastatic and Oligometastatic Disease
Stage IV non-small cell lung cancer means the cancer has spread beyond the primary lung and regional nodes. The most common sites of spread seen in Delhi NCR practice are the contralateral lung, pleura, bones, brain, liver and adrenal glands. Stage IVA (M1a and M1b) carries a meaningfully better prognosis than IVB (M1c), and oligometastatic IVA patients with a driver mutation or a single brain lesion now live many years on modern targeted therapy plus local ablation. Driver-negative IVB patients are treated with long-term disease control using chemo-immunotherapy rather than cure. Median overall survival for unselected stage IV NSCLC in Indian real-world data has improved from about 10 months a decade ago to 24 to 30 months today, and for driver-positive subsets it is often measured in years.
Limited-Stage Small Cell Lung Cancer
Limited-stage small cell lung cancer means disease confined to one hemithorax that can be covered by a single tolerable radiotherapy port, with or without ipsilateral mediastinal and supraclavicular nodes. About one in three SCLC patients present with limited-stage disease in Indian series. The standard of care is four to six cycles of cisplatin-etoposide with concurrent thoracic radiotherapy, typically 45 Gy in 30 fractions twice daily (the Turrisi schedule) or 66 Gy once daily over six and a half weeks, followed by prophylactic cranial irradiation in responders. After the 2024 ADRIATIC trial, consolidation durvalumab after chemoradiation is now offered at a tertiary cancer centre, a tertiary cancer centre Delhi, a tertiary cancer centre and a leading cancer centre to fit patients, and has improved five-year survival in this group to around 30 percent.
Extensive-Stage Small Cell Lung Cancer
Extensive-stage small cell lung cancer covers any SCLC that cannot fit inside a tolerable limited-stage radiotherapy port, including contralateral lung involvement, malignant effusion, or any distant metastasis. Two out of three SCLC patients present this way, and SCLC has the highest rate of brain metastases of any common solid tumour. First-line treatment is now carboplatin-etoposide plus atezolizumab, based on IMpower133, or carboplatin-etoposide plus durvalumab based on CASPIAN, with the checkpoint inhibitor continued as maintenance. Relapsed extensive-stage SCLC is treated with lurbinectedin, topotecan or, more recently, the BiTE therapy tarlatamab in DLL3-positive disease based on DeLLphi-301. Brain MRI surveillance every three months is standard at NCR tertiary centres.
Symptoms of Early Lung Cancer in India
Early lung cancer is almost always silent, which is the main reason Indian patients reach tertiary care late. A cough that has lasted more than three weeks, a change in the character of a long-standing smoker’s cough, or coughing up small amounts of blood are the three symptoms that should always trigger a chest imaging study in an adult over 40. Breathlessness on exertion, repeated chest infections in the same lobe, a dull ache in the chest or shoulder, hoarseness of voice and unexplained weight loss are the next most common presentations. In Delhi NCR, where ambient air pollution keeps bronchitis-type symptoms common through the winter, a lingering cough in a smoker is often treated as post-viral illness for weeks before a CT is ordered, and this diagnostic delay is a recognised driver of late-stage presentation in ICMR pollution-and-cancer studies.
Symptoms of Locally Advanced and Metastatic Lung Cancer
By the time a lung cancer has reached stage III, the tumour is often large enough or close enough to the airway and mediastinum to cause persistent chest pain, a hoarse voice from recurrent laryngeal nerve involvement, difficulty swallowing from oesophageal compression, or facial and arm swelling from superior vena cava obstruction. Pancoast tumours at the lung apex cause shoulder and arm pain with hand weakness. Stage IV disease brings symptoms from wherever the cancer has spread: bone metastases cause focal pain and pathological fractures, brain metastases cause headaches, seizures or new neurological deficits, liver metastases cause right upper abdominal discomfort, and adrenal spread is usually silent. A pleural effusion that keeps reaccumulating after drainage is another very common stage IV presentation in Indian practice.
Risk Factors: Tobacco, Bidi, Pollution and Occupational Exposures
Tobacco is still the single largest cause of lung cancer in India. Cigarette smoking, bidi smoking, hookah and chillum use all raise risk, and bidi smoking in some ICMR studies carries a squamous-cell risk comparable to or higher than cigarettes. Second-hand smoke at home or work is a meaningful driver for non-smokers, particularly women in households where a family member smokes indoors. A growing share of NCR lung cancer cases are now in lifelong non-smokers, especially women with EGFR-mutant adenocarcinoma, and indoor biomass cooking smoke, occupational exposures and ambient PM2.5 are all under active ICMR study. Outdoor air pollution is classified as a Group 1 carcinogen by IARC, and Delhi NCR PM2.5 values routinely exceed WHO guideline values in winter. (See the IARC Monograph 109 on outdoor air pollution.)
Diagnosis: Chest Imaging, Biopsy and EBUS-TBNA
Most lung cancer diagnoses in NCR begin with a chest X-ray for a persistent cough, followed by a contrast CT of the thorax and upper abdomen. The CT defines the primary lesion, mediastinal nodes, and picks up liver and adrenal involvement in the same study. When the CT shows a suspicious mass, the next step is tissue sampling. Peripheral lesions are usually sampled by CT-guided trans-thoracic core needle biopsy. Central lesions and suspicious mediastinal nodes are approached with flexible bronchoscopy, endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) or, less commonly now, mediastinoscopy. a tertiary cancer centre, a tertiary cancer centre and the larger NCR centres run dedicated EBUS lists because accurate N-staging changes treatment intent from curative surgery to combined chemoradiation.
Molecular Testing Panel Every NSCLC Patient Needs in 2026
Once a non-squamous non-small cell lung cancer is confirmed, Indian guidelines and ESMO both recommend reflex molecular testing on the same tissue block before any systemic therapy is started. The minimum 2026 panel includes EGFR (exon 19 deletions, L858R, T790M and uncommon mutations), ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14 skipping, RET fusions, NTRK fusions and HER2, and where the block allows, a broader DNA-plus-RNA next generation sequencing panel. Starting chemotherapy before these results are back wastes months of response time that a targeted pill could buy, and in EGFR-mutant disease can even worsen toxicity when osimertinib is later added. (See the ESMO lung cancer guidelines page.)
PD-L1 Testing and Why It Decides First-Line Immunotherapy
Programmed death ligand 1 (PD-L1) immunohistochemistry is now done on every non-small cell lung cancer at diagnosis, because it is the single biomarker that decides whether a metastatic driver-negative patient qualifies for first-line pembrolizumab monotherapy. PD-L1 expression is scored as the tumour proportion score (TPS) using the 22C3 or SP263 clone. A TPS of 50 percent or more makes the patient eligible for single-agent pembrolizumab based on KEYNOTE-024, cemiplimab based on EMPOWER-Lung 1, or atezolizumab based on IMpower110. A TPS between 1 and 49 percent, and PD-L1 negative tumours, go to chemo-immunotherapy combinations such as KEYNOTE-189 for non-squamous and KEYNOTE-407 for squamous disease.
Staging Investigations: PET-CT and Brain MRI
Once histology and molecular testing are under way, formal staging investigations for non-small cell lung cancer include an FDG PET-CT from skull base to mid-thigh and a contrast brain MRI. PET-CT picks up distant nodes, bone and unexpected visceral metastases that would change management, and brain MRI is preferred over CT because small metastases are routinely missed on CT alone and would turn a supposed stage III into stage IV. For small cell lung cancer, the same PET-CT plus brain MRI approach has now replaced the old limited-versus-extensive CT work-up at most NCR tertiary centres. Baseline pulmonary function tests, a six minute walk test where relevant, an ECG and 2D-echo complete the fitness assessment before surgery, curative radiotherapy or concurrent chemoradiation.
Treatment of Stage I and II NSCLC: Lobectomy and SBRT
Stage I and II non-small cell lung cancer is managed with curative intent. The standard of care is anatomic lobectomy with systematic mediastinal lymph node dissection, performed open, VATS or robotic depending on the centre. For very small peripheral tumours up to 2 cm, the CALGB 140503 trial and JCOG 0802 showed that sublobar resection (segmentectomy or wide wedge) gives non-inferior survival compared with lobectomy in selected stage IA patients, and segmentectomy is now used routinely at leading cancer centres in the region for carefully chosen cases. Patients who are medically unfit for surgery are offered stereotactic body radiotherapy (SBRT), typically 48 to 60 Gy in 3 to 8 fractions, with local control rates above 90 percent at three years in RTOG 0236 and CHISEL.
Adjuvant and Neoadjuvant Therapy in Resectable NSCLC
Adjuvant systemic therapy after lung cancer surgery depends on stage, histology and molecular profile. Stage IB high-risk, II and IIIA disease receive four cycles of adjuvant platinum doublet chemotherapy, most commonly cisplatin plus vinorelbine or carboplatin plus paclitaxel, based on the LACE meta-analysis and JBR.10. EGFR-mutant resected stage IB to IIIA NSCLC now receives three years of adjuvant osimertinib based on ADAURA. PD-L1 positive, EGFR and ALK wild-type resected stage II to IIIA NSCLC is offered one year of adjuvant atezolizumab based on IMpower010, or adjuvant pembrolizumab based on KEYNOTE-091. Neoadjuvant nivolumab plus chemotherapy for three cycles before surgery is now an option in resectable stage II to IIIA disease based on CheckMate 816. Perioperative regimens from AEGEAN, KEYNOTE-671, Neotorch and CheckMate 77T are used at NCR tertiary centres with payer support.
Treatment of Unresectable Stage III NSCLC: PACIFIC and LAURA
Unresectable stage III non-small cell lung cancer is treated with concurrent platinum-based chemoradiation to 60 to 66 Gy, using cisplatin-etoposide or weekly carboplatin-paclitaxel as the radio-sensitising doublet, followed by one year of consolidation durvalumab based on the PACIFIC trial, which remains the single practice-changing study in this space and has been standard at a tertiary cancer centre, a tertiary cancer centre Delhi, a tertiary cancer centre and a leading cancer centre for several years. The LAURA trial has now added consolidation osimertinib after chemoradiation for EGFR-mutant unresectable stage III disease. Patients who cannot tolerate concurrent chemoradiation are treated with sequential chemotherapy followed by radiotherapy, with a lower expected survival benefit. Multidisciplinary thoracic tumour boards decide each case individually.
Treatment of Driver-Positive Stage IV NSCLC
Stage IV driver-positive non-small cell lung cancer is where molecular profiling drives almost every decision. EGFR-mutant metastatic NSCLC is treated first-line with osimertinib based on FLAURA, and the 2024 FLAURA2 regimen (osimertinib plus pemetrexed-platinum) and the MARIPOSA regimen (amivantamab plus lazertinib) are now options for higher-risk subgroups. ALK-positive disease uses first-line alectinib (ALEX), brigatinib (ALTA-1L) or lorlatinib (CROWN), with the CROWN five-year update showing the longest first-line PFS ever reported in metastatic solid tumour oncology. ROS1-positive disease uses entrectinib or repotrectinib, BRAF V600E uses dabrafenib-trametinib, MET exon 14 uses capmatinib or tepotinib, RET fusions use selpercatinib, KRAS G12C uses sotorasib or adagrasib, HER2 mutant uses trastuzumab deruxtecan, and NTRK fusions use larotrectinib or entrectinib.
Treatment of Driver-Negative Stage IV NSCLC
Driver-negative metastatic non-small cell lung cancer is stratified by PD-L1 expression and histology. PD-L1 TPS at or above 50 percent gets first-line pembrolizumab monotherapy based on KEYNOTE-024, cemiplimab based on EMPOWER-Lung 1, or atezolizumab based on IMpower110. All-comer first-line options for non-squamous disease include pembrolizumab plus pemetrexed-platinum based on KEYNOTE-189, and for squamous disease pembrolizumab plus carboplatin-paclitaxel or nab-paclitaxel based on KEYNOTE-407. Nivolumab plus ipilimumab plus two cycles of chemotherapy (CheckMate 9LA) is another first-line option. Second-line and beyond uses docetaxel plus nintedanib (LUME-Lung 1) or docetaxel plus ramucirumab (REVEL), and trastuzumab deruxtecan for HER2-overexpressing disease.
Treatment of Limited and Extensive-Stage SCLC
Small cell lung cancer treatment has finally moved after two decades of stagnation. Limited-stage SCLC is treated with four to six cycles of cisplatin-etoposide plus concurrent thoracic radiotherapy, typically 45 Gy in 30 fractions twice daily (CONVERT, Turrisi) or 66 Gy once daily, followed by prophylactic cranial irradiation in responders, and now consolidation durvalumab based on ADRIATIC. Extensive-stage first-line is carboplatin-etoposide plus atezolizumab (IMpower133) or plus durvalumab (CASPIAN), with the checkpoint inhibitor continued as maintenance. Relapsed SCLC is treated with lurbinectedin, topotecan or tarlatamab, the first DLL3-directed BiTE, based on DeLLphi-301. Brain MRI surveillance every three months is standard in NCR tertiary practice.
Cost of Lung Cancer Treatment in Delhi, Gurgaon and Noida
Lung cancer costs in the Delhi capital region vary more than any other solid tumour because the mix of surgery, radiation, systemic therapy and molecular testing can look very different from one patient to the next. A contrast CT chest runs about ₹4,500 to ₹12,000, a whole body FDG PET-CT is ₹18,000 to ₹28,000, brain MRI with contrast is ₹8,000 to ₹15,000, and EBUS-TBNA is ₹35,000 to ₹75,000 in private NCR hospitals and roughly ₹8,000 at a tertiary cancer centre. A full DNA-plus-RNA NGS panel is ₹55,000 to ₹1,20,000 in private labs. VATS lobectomy sits in the ₹2,50,000 to ₹4,50,000 band at a tertiary cancer centre and a tertiary cancer centre and ₹4,50,000 to ₹10,00,000 at leading cancer centres in the region. IMRT for a stage III plan is ₹2,50,000 to ₹8,00,000 depending on centre. Osimertinib (80 mg daily) in generic Indian form runs ₹12,000 to ₹25,000 a month, while branded Tagrisso is ₹1,50,000 to ₹1,80,000. Pembrolizumab 200 mg is ₹1,60,000 to ₹2,10,000 a vial, and a full year of consolidation durvalumab after chemoradiation sits in the ₹35,00,000 to ₹52,00,000 band before any access discount. PMJAY covers listed oncology packages up to ₹5,00,000 per family per year at empanelled NCR hospitals including leading cancer centres, and CGHS, ECHS, DGEHS and Delhi Arogya Kosh fund their respective beneficiaries. The Health Minister’s Cancer Patient Fund at a tertiary cancer centre and patient access programmes from Cipla, Natco, Dr Reddy’s and a leading cancer centre Foundation close the gap for catastrophic cases. (See PMJAY and the HMCPF.)
Frequently Asked Questions About Lung Cancer Stages
Is lung cancer always caused by smoking? No. Around 15 to 20 percent of Indian lung cancer patients have never smoked, and in women that share is even higher. Second-hand smoke, long-term exposure to Delhi NCR PM2.5, indoor biomass smoke, asbestos, silica, radon and inherited factors all contribute, and never-smoker Indian lung cancers are more likely to be adenocarcinoma with a targetable driver mutation.
My father has a 1.2 cm ground glass nodule on CT. Is it cancer? Ground glass nodules are often indolent adenocarcinoma in situ or minimally invasive adenocarcinoma, and many stay stable for years. The standard approach in NCR tertiary centres is a repeat thin-section CT in three to six months rather than an immediate biopsy, with PET-CT reserved for solid or growing lesions. Do not rush into surgery before a pulmonologist or thoracic oncologist has reviewed serial scans.
Why is molecular testing done before chemotherapy? Because giving chemotherapy to an EGFR, ALK, ROS1, RET or MET driven NSCLC wastes months of response time that a targeted pill would buy. The median PFS on first-line osimertinib in EGFR-mutant disease is around 19 months, and on first-line lorlatinib in ALK-positive disease the five-year PFS is above 60 percent. (See the NCI NSCLC PDQ.)
Can lung cancer be cured? Yes, if it is caught early. Stage I NSCLC treated with lobectomy or SBRT has five-year survival in the 70 to 90 percent range. Stage II is around 50 to 60 percent. Stage III falls to 25 to 40 percent depending on substage and treatment intent. Stage IV is usually treated with long-term disease control rather than cure, though oligometastatic and driver-positive patients on modern therapy now live many years.
Is immunotherapy available at a tertiary cancer centre and government hospitals? Yes. leading cancer centres and Delhi State Cancer Institute all use pembrolizumab, nivolumab, atezolizumab and durvalumab, though access is often rationed by PMJAY eligibility, the HMCPF and patient access programmes. Private centres have wider protocol flexibility.
Is SBRT safe for an 80-year-old with emphysema? Yes. SBRT is specifically designed for patients who are not candidates for lobectomy. Studies including RTOG 0236 and CHISEL showed that carefully planned SBRT delivers high local control with low rates of severe toxicity in elderly and frail patients, and it is routinely offered in NCR to patients who cannot tolerate surgery.
My sibling has limited-stage small cell lung cancer. Is it curable? Limited-stage SCLC means the disease is confined to one half of the chest and can be covered by a single tolerable radiotherapy port. With concurrent chemoradiation, prophylactic cranial irradiation in responders and now consolidation durvalumab after ADRIATIC, five-year survival for limited-stage SCLC has improved to roughly 30 percent at experienced centres.
How long does a full lung cancer work-up take in NCR? A motivated family can usually complete biopsy, histology with IHC, molecular testing, PET-CT, brain MRI and tumour board discussion within 10 to 14 working days at a private tertiary centre, and 2 to 4 weeks at a government centre. Starting treatment within four weeks of histological diagnosis is associated with better outcomes.
Should I get a second opinion before starting treatment? Yes. A tumour board review at a second comprehensive cancer centre is strongly recommended for any stage III NSCLC, any borderline-resectable case, any uncommon driver mutation and any SCLC with unusual features. Most NCR tertiary centres offer formal second-opinion clinics and accept outside slides and blocks for review.
Overview
Treatment Options